Android app on Google Play

Pre-Open Stock Movers 11/27: (FRO) (GWPH) (HPQ) Higher; (TLYS) (BLOX) (ADI) Lower (more...)

November 27, 2013 9:27 AM EST Send to a Friend
Tillys (NYSE: TLYS) 23.2% LOWER; reported Q3 EPS of $0.22, $0.01 better than the analyst estimate of $0.21. Revenue for the quarter came in at $123.8 million versus the consensus estimate of $132.6 million. Comps fell 2.4%. Tillys sees Q4 2013 EPS of $0.15-$0.20, versus the consensus of $0.35.

Infoblox (NYSE: BLOX) 22% LOWER; reported Q1 EPS of $0.12, $0.03 better than the analyst estimate of $0.09. Revenue for the quarter came in at $63.5 million versus the consensus estimate of $63.5 million. Infoblox sees Q2 2013 EPS of $0.09 - $0.11, versus the consensus of $0.12. Total net revenue in the range of $65 million to $66 million, while the Street is at $67.0 million. Non-GAAP gross margin to be between 78% to 79%. Non-GAAP operating margin in the range of 9% to 11% Infoblox sees FY2013 EPS of $0.44 - $0.54, versus prior guidance of $0.44 - $0.55 and the consensus of $0.53. Total net revenue in the range of $270 million to $276 million, versus expectations of $276.9 million. Non-GAAP operating margin in the range of 10.5% to 12.5%

Frontline (NYSE: FRO) 12% HIGHER; reported Q3 EPS of ($0.46), $0.01 better than the analyst estimate of ($0.47).

GW Pharma (NASDAQ: GWPH) 8.7% HIGHER; Piper Jaffray initiates coverage with an Overweight. PT $73.00

Hewlett-Packard Company (NYSE: HPQ) 6.9% HIGHER; reported Q4 EPS of $1.01, $0.01 better than the analyst estimate of $1.00. Revenue for the quarter came in at $29.1 billion versus the consensus estimate of $27.91 billion.

Mediabistro Inc. (Nasdaq: MBIS) 22% LOWER; gives back some of yesterday's 89% gains.

Durata Therapeutics, Inc. (Nasdaq: DRTX) 4.8% HIGHER; announced that the New Drug Application (NDA) for its investigational drug, Dalvance (dalbavancin hydrochloride) for injection, has been accepted for priority review by the U.S. Food and Drug Administration (FDA) with an action date of May 26, 2014. Durata is seeking FDA approval of Dalvance™ for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive microorganisms, including MRSA (methicillin resistant Staphylococcus aureus).

Crocs, Inc. (Nasaq: CROX) ; is in talks wtih Blackstone (NYSE: BX) and others about a possible investment, according to Bloomberg sources.

Camtek Ltd. (NASDAQ: CAMT) 4.8% HIGHER; continues recent momentum

Foster Wheeler AG (NASDAQ: FWLT) 4.6% HIGHER; takeover speculation

AeroVironment, Inc. (NASDAQ: AVAV) 4.4% HIGHER; reported Q2 EPS of $0.07, may not compare to the analyst estimate of $0.07. Revenue for the quarter came in at $64.9 million versus the consensus estimate of $56.64 million. AeroVironment, Inc. sees FY2013 EPS of $0.35-$0.50, versus the consensus of $0.37. AeroVironment, Inc. sees FY2013 revenue of $230-250 million, versus the consensus of $234.6 million.

Analog Devices, Inc. (NASDAQ: ADI) 3.3% LOWER; reported Q4 EPS of $0.62, $0.04 better than the analyst estimate of $0.58. Revenue for the quarter came in at $678 million versus the consensus estimate of $688.5 million. Sees Q1 2014 EPS of $0.44-$0.52, versus the consensus of $0.56. Revenue estimated to decrease in the range of -5% to -10%

Ruckus Wireless (NYSE: RKUS) 3.2 HIGHER; Stifel Nicolaus initiates coverage with a Buy and price target of $17.

Repros Therapeutics (NASDAQ: RPRX) 3.2% HIGHER; Piper Jaffray initiates coverage with a Overweight. PT $26.

Insmed Incorporated (NASDAQ: INSM) 1.8% HIGHER; Piper Jaffray initiates coverage with an Overweight. PT $34.00

Shanda Games Ltd. (NASDAQ: GAME) 1.5% LOWER; reported Q3 EPS of $0.26, $0.03 better than the analyst estimate of $0.23. Revenue for the quarter came in at $182.9 million versus the consensus estimate of $183.7 million.

GNC Holdings (NYSE: GNC) 1.4% HIGHER; announced its Board of Directors has authorized a multi-year program to repurchase up to an aggregate $500 million of the Company's Class A common stock. The authorization is effective immediately. The Company may finance any repurchases with cash, potential financing transactions, or a combination of the foregoing. All previous share repurchase authorizations have been completed.

Zale Corp. (NYSE: ZLC) 1.2% LOWER; reported Q1 EPS of ($0.83), $0.03 better than the analyst estimate of ($0.86). Revenue for the quarter came in at $363 million versus the consensus estimate of $362.42 million. Comparable store sales up 4.4 percent; up 5.4 percent at constant exchange rates.

Tesla Motors, Inc. (NASDAQ: TSLA) 1% HIGHER; Deutsche Bank defends the stock

Compuware Corporation (NASDAQ: CPWR) 1% HIGHER; renewed takeover reports.




You May Also Be Interested In


Related Categories

Special Reports

Related Entities

Piper Jaffray, Stifel Nicolaus, Deutsche Bank, Stock Buyback, Tesla

Add Your Comment